NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-11-30
DOI
10.3389/fonc.2020.593578
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
- (2020) Daniel J. Brat et al. ACTA NEUROPATHOLOGICA
- Tropomyosin receptor kinase inhibitors: an updated patent review for 2016 – 2019
- (2020) Justin J Bailey et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology
- (2020) Yoichi Naito et al. International Journal of Clinical Oncology
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Patterns of somatic structural variation in human cancer genomes
- (2020) Yilong Li et al. NATURE
- TRK Inhibitors in Non-Small Cell Lung Cancer
- (2020) Guilherme Harada et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Glioblastomas harboring gene fusions detected by next-generation sequencing
- (2020) Ha Young Woo et al. Brain Tumor Pathology
- Molecular and clinicopathologic features of gliomas harboring NTRK fusions
- (2020) Matthew Torre et al. Acta Neuropathologica Communications
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
- (2019) Ulrich Herrlinger et al. LANCET
- Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.
- (2019) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Testing algorithm for identification of patients with TRK fusion cancer
- (2019) Frédérique Penault-Llorca et al. JOURNAL OF CLINICAL PATHOLOGY
- Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from TRK Inhibitor Therapy
- (2019) Susan J. Hsiao et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
- (2019) Chia-Chi Lin et al. BRITISH JOURNAL OF CANCER
- Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms
- (2019) James P. Solomon et al. CANCER RESEARCH
- Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
- (2019) Derek Wong et al. PATHOLOGY & ONCOLOGY RESEARCH
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
- (2019) James P. Solomon et al. MODERN PATHOLOGY
- Resistance to TRK inhibition mediated by convergent MAPK pathway activation
- (2019) Emiliano Cocco et al. NATURE MEDICINE
- TRK inhibitors in TRK fusion-positive cancers
- (2019) A Drilon ANNALS OF ONCOLOGY
- Molecular targeted therapy of glioblastoma
- (2019) Emilie Le Rhun et al. CANCER TREATMENT REVIEWS
- Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma
- (2019) Xi Chen et al. Molecular Oncology
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016
- (2019) Quinn T Ostrom et al. NEURO-ONCOLOGY
- TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
- (2019) Ezra Y Rosen et al. CLINICAL CANCER RESEARCH
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
- (2018) Sherise D Ferguson et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment
- (2018) Tao Xu et al. Translational Oncology
- Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling
- (2018) Barbara Oldrini et al. Nature Communications
- Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
- (2018) Bruce W. Konicek et al. Oncotarget
- cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
- (2018) Daniel J. Brat et al. ACTA NEUROPATHOLOGICA
- Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma
- (2018) David S. Ziegler et al. BRITISH JOURNAL OF CANCER
- The Use of Neoadjuvant Larotrectinib in the Management of Children With Locally Advanced TRK Fusion Sarcomas
- (2018) Steven G. DuBois et al. CANCER
- Molecular characterization of cancers with NTRK gene fusions
- (2018) Zoran Gatalica et al. MODERN PATHOLOGY
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
- (2018) Alexander Drilon et al. Cancer Discovery
- Larotrectinib for the treatment of TRK fusion solid tumors
- (2018) Theodore W. Laetsch et al. Expert Review of Anticancer Therapy
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy
- (2017) Alanna J Church et al. MODERN PATHOLOGY
- Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
- (2017) Miho J. Fuse et al. MOLECULAR CANCER THERAPEUTICS
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy
- (2017) Timothy F Cloughesy et al. NEURO-ONCOLOGY
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
- (2017) Patrick Y Wen et al. NEURO-ONCOLOGY
- Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target
- (2017) Peter J. Cook et al. Nature Communications
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing
- (2017) Danielle A. Murphy et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Mammary Analogue Secretory Carcinoma of Salivary Glands
- (2016) Alena Skálová et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Tyrosine receptor kinase B is a drug target in astrocytomas
- (2016) Jing Ni et al. NEURO-ONCOLOGY
- Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
- (2015) Roger Stupp et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
- (2014) Gang Wu et al. NATURE GENETICS
- Anchored multiplex PCR for targeted next-generation sequencing
- (2014) Zongli Zheng et al. NATURE MEDICINE
- NTRK1 Fusion in Glioblastoma Multiforme
- (2014) Jinkuk Kim et al. PLoS One
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data
- (2013) Nameeta Shah et al. BMC GENOMICS
- The integrated landscape of driver genomic alterations in glioblastoma
- (2013) Veronique Frattini et al. NATURE GENETICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now